A chemical found in broccoli sprouts may help in alleviating behavioral symptoms associated with autism spectrum disorder, according to a small study.
Paul Talalay, MD, of the Johns Hopkins School of Medicine in Baltimore, Maryland, and colleagues examined 40 teenage boys and young men, aged between 13 and 27, with moderate to severe autism.
Those in the group who received a daily dose of sulforaphane over an 18-week period saw significant improvement in social interaction and verbal communication, and a decrease in repetitive behaviors, compared to those on placebo, the researchers reported in the Proceedings of the National Academy of Sciences.
The reason why sulforaphane may work on autism has to do with the chemical’s heat-shock response on the body and the fact that many parents report that their children’s autistic behaviors improve when they have a fever.
Fevers and sulforaphane both initiate the heat shock-response. Researchers investigated whether sulforaphane would lead to the same improvement in autism symptoms as having a fever often does.
When the patients stopped taking the chemical, the autism symptoms returned.
“It seems like sulforaphane is temporarily helping cells to cope with their handicaps,” Talalay said in a statement.
Autism spectrum disorder (ASD), encompassing impaired communication and social interaction, and repetitive stereotypic behavior and language, affects 1–2% of predominantly male individuals and is an enormous medical and economic problem for which there is no documented, mechanism-based treatment.
In a placebo-controlled, randomized, double-blind clinical trial, daily oral administration for 18 weeks of the phytochemical sulforaphane (derived from broccoli sprouts) to 29 young men with ASD substantially (and reversibly) improved behavior compared with 15 placebo recipients. Behavior was quantified by both parents/caregivers and physicians by three widely accepted measures.
Enjoying our content?
Thanks for visiting Psychiatry Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Psychiatry Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Evidence-Based Guidance
- Conference Coverage
- Unique Psychiatry Case Studies
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.